Biohit
| Public (OMX: BIOBV.B) | |
| Industry | Medical equipment |
| Founder | Osmo Suovaniemi |
| Headquarters | Helsinki, Finland |
Area served | Worldwide |
Key people | Osmo Suovaniemi (Founder and Chairman of the Board), Semi Korpela (President and CEO) |
| Products | liquid handling equipment |
| Total equity | €23.9 million (2010) |
Biohit Oyj is a Finnish company which develops, manufactures, and markets diagnostics products for use in research and health care.
Summary
Biohit was established in 1988 in Finland by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of Labsystems.[1][2] He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health”. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Mr Semi Korpela was appointed CEO in 2011.
Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. Biohit´s research and development combines expertise in various fields into integrated know-how. Biohit’s personnel together with scientific advisers representing various academic communities apply their knowledge in basic and applied research to develop innovative products for laboratories and the health care industry. The multidisciplinary approach, innovations and application has produced valuable results for the advancement of research and health care all over the world. A further strength of Biohit’s multidisciplinary R & D is the ability to react quickly to new customer needs and product ideas.
All of Biohit’s products and processes from R&D to production and from marketing to sales comply with ISO 13485 quality standards, which cover the manufacture of medical device, and also with ISO 9001 and ISO 14001 quality and environmental standards. Biohit’s products are also CE/IVD (In Vitro Diagnostics) registered and approved.
Biohit manufactures almost all of its products itself, using clean rooms, demanding raw materials. •The Quality Management System of Biohit complies with the ISO 9001 and the ISO 13485 •The Biohit Environmental Quality Management complies with the ISO 14001 Environmental standard. •Certified by Det Norske Veritas (DNV)
Markets
Biohit's two businesses are acetaldehyde eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland [3]
Diagnostic tests
The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron. In addition to this, Biohit offers Quick tests for the detection of •Lactose intolerance •Helicobacter pylori infection •Celiac disease •Screening of colorectal cancer
Acetaldehyde binding products
An acid-free stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer. Acetium® is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid or anacidic stomach
Monoclonal antibodies
Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for diagnostic industry.
Instruments
Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.
Distribution Network
A network of 40 distributors, including 2 subsidiaries, in more than 40 countries is selling Biohit products.
Research, Development, and Intellectual Property
Biohit spends roughly 30% of net sales on basic research each year and pursues an aggressive patenting strategy.[4]
In 2014 Biohit started studies on migraine and cluster headache prevention with Acetium capsules.[5] [6]
References
- ↑ Harriet Öster (8 October 1998). "Labsystems kasvaa suuren suojassa". Tekniikka & Talous. Retrieved 2009-11-15.
- ↑ Osmo Suovaniemi, Helena Hentola (2004). "Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being" (PDF). Biohit.
- ↑ Biohit Oyj. Annual Report 2012
- ↑ Reuters. Overview of Biomet Oyj. http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=BIOBV.HE
- ↑ The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients https://clinicaltrials.gov/ct2/show/NCT02315833
- ↑ The Efficacy of L-cysteine in Prevention of Cluster Headache https://clinicaltrials.gov/ct2/show/NCT02310828